Liquid Biopsies in Ewing Sarcoma
Liquid biopsies enable noninvasive therapy monitoring in patients with solid tumors. Specific serum markers such as proteins, hormones, or enzymes released from tumor cells or in response to tumor growth can be used for quantification of the tumor burden. However, only a fraction of pediatric tumors has none of these serum markers, but tumor-specific genetic alterations represent reliable alternatives. Here we describe a method for using genomic fusion sequences as liquid biopsy markers in Ewing sarcoma patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2226 |
|---|---|
| Enthalten in: |
Methods in molecular biology (Clifton, N.J.) - 2226(2021) vom: 16., Seite 39-45 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Krumbholz, Manuela [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers, Tumor |
|---|
| Anmerkungen: |
Date Completed 01.04.2021 Date Revised 01.04.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1007/978-1-0716-1020-6_4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318911841 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318911841 | ||
| 003 | DE-627 | ||
| 005 | 20231225170343.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/978-1-0716-1020-6_4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1063.xml |
| 035 | |a (DE-627)NLM318911841 | ||
| 035 | |a (NLM)33326092 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Krumbholz, Manuela |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Liquid Biopsies in Ewing Sarcoma |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.04.2021 | ||
| 500 | |a Date Revised 01.04.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Liquid biopsies enable noninvasive therapy monitoring in patients with solid tumors. Specific serum markers such as proteins, hormones, or enzymes released from tumor cells or in response to tumor growth can be used for quantification of the tumor burden. However, only a fraction of pediatric tumors has none of these serum markers, but tumor-specific genetic alterations represent reliable alternatives. Here we describe a method for using genomic fusion sequences as liquid biopsy markers in Ewing sarcoma patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cell-free circulating DNA | |
| 650 | 4 | |a Double-quenched probes | |
| 650 | 4 | |a Droplet digital PCR | |
| 650 | 4 | |a Ewing sarcoma | |
| 650 | 4 | |a Genomic fusion sequences | |
| 650 | 4 | |a Liquid biopsy | |
| 650 | 4 | |a Serum marker | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 650 | 7 | |a Circulating Tumor DNA |2 NLM | |
| 700 | 1 | |a Metzler, Markus |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Methods in molecular biology (Clifton, N.J.) |d 1984 |g 2226(2021) vom: 16., Seite 39-45 |w (DE-627)NLM074849794 |x 1940-6029 |7 nnns |
| 773 | 1 | 8 | |g volume:2226 |g year:2021 |g day:16 |g pages:39-45 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/978-1-0716-1020-6_4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 2226 |j 2021 |b 16 |h 39-45 | ||